Ftse Mib
34.160,97
1,25%
DAX
19.984,32
0,74%
S&P 500
5.970,84
-1,11%
NASDAQ
19.722,03
-1,49%
Bitcoin
94.232,75
0,08%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Edgewise Therapeutics Inc (EWTX) Edgewise Therapeutics Inc (EWTX) Notizie

EWTX

Edgewise Therapeutics (EWTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EWTX
DataOraFonteTitoloSimboloCompagnia
16/12/202423:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
16/12/202412:00Business WireEdgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)NASDAQ:EWTXEdgewise Therapeutics Inc
05/12/202420:32Business WireEdgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease ResearchNASDAQ:EWTXEdgewise Therapeutics Inc
26/11/202412:00Business WireEdgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
07/11/202414:53Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EWTXEdgewise Therapeutics Inc
07/11/202414:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EWTXEdgewise Therapeutics Inc
07/11/202414:00Business WireEdgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
01/10/202414:00Business WireEdgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle SocietyNASDAQ:EWTXEdgewise Therapeutics Inc
25/09/202402:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EWTXEdgewise Therapeutics Inc
20/09/202422:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EWTXEdgewise Therapeutics Inc
19/09/202413:00Business WireEdgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)NASDAQ:EWTXEdgewise Therapeutics Inc
17/09/202422:01Business WireEdgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern TimeNASDAQ:EWTXEdgewise Therapeutics Inc
08/08/202414:00Business WireEdgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
10/05/202415:07Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:EWTXEdgewise Therapeutics Inc
10/05/202414:00Business WireEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
09/05/202414:00Business WireEdgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
07/05/202415:16Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EWTXEdgewise Therapeutics Inc
07/05/202414:00Business WireEdgewise Therapeutics Appoints Arlene Morris to its Board of DirectorsNASDAQ:EWTXEdgewise Therapeutics Inc
06/05/202414:00Business WireEdgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)NASDAQ:EWTXEdgewise Therapeutics Inc
23/04/202414:00Business WireEdgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular DystrophiesNASDAQ:EWTXEdgewise Therapeutics Inc
15/04/202422:05Business WireEdgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)NASDAQ:EWTXEdgewise Therapeutics Inc
28/03/202413:00Business WireEdgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific SessionNASDAQ:EWTXEdgewise Therapeutics Inc
27/03/202413:00Business WireEdgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
05/03/202414:00Business WireEdgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
28/02/202414:00Business WireEdgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific ConferenceNASDAQ:EWTXEdgewise Therapeutics Inc
22/02/202414:07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EWTXEdgewise Therapeutics Inc
22/02/202414:00Business WireEdgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
14/02/202414:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EWTXEdgewise Therapeutics Inc
13/02/202414:00Business WireEdgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)NASDAQ:EWTXEdgewise Therapeutics Inc
19/01/202422:54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EWTXEdgewise Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EWTX

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
SRG
Snam
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
SPM
Saipem
BIT
LDO
Leonardo
BIT
PRY
Prysmian
BIT
TEN
Tenaris
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network